MaaT Pharma SA
EPA:MAAT.PA
7.14 (EUR) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 2.228 | 1.43 | 0.972 | 0 | 0.089 | 0.892 | 0.109 |
| Cost of Revenue
| 1.444 | 0.339 | 0.166 | 0.164 | 0.097 | 0.079 | 3.501 |
| Gross Profit
| 0.784 | 1.091 | 0.806 | -0.164 | -0.008 | 0.813 | -3.391 |
| Gross Profit Ratio
| 0.352 | 0.763 | 0.829 | 0 | -0.086 | 0.911 | -31.022 |
| Reseach & Development Expenses
| 20.297 | 14.476 | 9.145 | 6.099 | 5.269 | 4.509 | 0 |
| General & Administrative Expenses
| 2.552 | 1.465 | 1.167 | 1.289 | 0.922 | 0.787 | 0 |
| Selling & Marketing Expenses
| 0.449 | 0.347 | 0.217 | 0.099 | 0 | 0 | 0 |
| SG&A
| 5.097 | 1.812 | 1.384 | 1.289 | 0.922 | 0.787 | 1.265 |
| Other Expenses
| 0 | -1.641 | -0.83 | -2.135 | -1.226 | -0.892 | 0 |
| Operating Expenses
| 25.394 | 14.647 | 9.699 | 5.253 | 4.965 | 4.404 | 1.317 |
| Operating Income
| -24.61 | -13.556 | -8.893 | -5.252 | -4.965 | -4.404 | -4.708 |
| Operating Income Ratio
| -11.046 | -9.48 | -9.149 | 0 | -55.597 | -4.937 | -43.066 |
| Total Other Income Expenses Net
| 1.26 | -0.157 | -0.126 | -0.049 | -0.879 | -0.071 | -0.073 |
| Income Before Tax
| -23.35 | -13.713 | -9.019 | -5.301 | -5.844 | -4.475 | -4.781 |
| Income Before Tax Ratio
| -10.48 | -9.59 | -9.279 | 0 | -65.439 | -5.017 | -43.736 |
| Income Tax Expense
| -3.633 | 0.157 | 0.121 | 0.049 | 0.803 | 0.071 | 0.923 |
| Net Income
| -19.717 | -13.87 | -9.14 | -5.35 | -6.647 | -4.546 | -3.858 |
| Net Income Ratio
| -8.85 | -9.699 | -9.403 | 0 | -74.431 | -5.096 | -35.295 |
| EPS
| -1.73 | -1.4 | -3.77 | -25.91 | -32.2 | -4.4 | 0 |
| EPS Diluted
| -1.73 | -1.4 | -3.77 | -25.91 | -32.2 | -4.4 | 0 |
| EBITDA
| -23.739 | -13.099 | -8.57 | -5.088 | -4.944 | -4.325 | -4.657 |
| EBITDA Ratio
| -10.655 | -9.16 | -8.817 | 0 | -55.361 | -4.849 | -42.597 |